BRAF and cancer: Besides, resistance to all types of TKIs can be acquired by activation of alternative pathways in the proliferation of cancer cells, which can be achieved with BRAF (murine sarcoma viral oncogene homolog B1) mutation and MET (hepatocyte growth factor receptor) or HER2 (human epidermal growth factor receptor 2) amplification [49].